Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › ustekinumab

ustekinumab

6 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of ustekinumab

33 trials tracked of ustekinumab: 18 in phase 3 or 4 and 10 with published results. The most-cited published study has 97 citations.

33Trials tracked
18Phase 3 & 4
0Recruiting
10With published results
Phase distribution
Phase 4 3 Phase 3 15 Phase 2 11 Phase 1 3 Other / NA 1
  1. Phase 3 Study of Treat to Target Versus Routine Care Maintenance Strategies in Crohn's Disease Patients Treated With Ustekinumab Completed · 97 cited
  2. Phase 3 Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis Completed · 75 cited
  3. Phase 3 A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis Completed · 57 cited
  4. Phase 3 A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab Completed · 54 cited
  5. Phase 3 BI 655066 (Risankizumab) Compared to Placebo and Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis Completed · 53 cited
  6. Phase 3 BI 655066 Versus Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis Completed · 53 cited
Show 27 more trials
  1. Phase 3 A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis Completed · 39 cited
  2. Phase 3 A Study to Investigate ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis Completed · 14 cited
  3. Phase 3 A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease Completed · 4 cited
  4. Phase 3 Loss of RESponse to Ustekinumab Treated by Dose Escalation Completed
  5. Phase 4 Vascular Inflammation in Psoriasis-Ustekinumab (VIP-U) Completed
  6. Phase 4 A Safety and Efficacy Study of Ustekinumab in Patients With Plaque Psoriasis Who Have Had an Inadequate Response to Methotrexate Completed
  7. Phase 4 The Quality of Life Study in Psoriasis Patients After Ustekinumab Treatment Completed
  8. Phase 3 A Study to Investigate Interchangeability of ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis Completed
  9. Phase 3 A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms Completed
  10. Phase 3 Efficacy of Secukinumab Compared to Ustekinumab in Adults With Active Psoriatic Arthritis and Failure of TNFα-Inhibitor Treatment Completed
  11. Phase 3 A Study of Safety and Effectiveness of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Plaque-type Psoriasis Completed
  12. Phase 3 A Study of the Safety and Effectiveness of Ustekinumab (Stelara) in Chinese Patients With Psoriasis Completed
  13. Phase 2 Tacrolimus, Sirolimus and Ustekinumab vs. Tacrolimus and Sirolimus for the Prevention of Acute Graft-Versus-Host Disease Completed
  14. Phase 2 BI 655066 Dose Ranging in Psoriasis, Active Comparator Ustekinumab Completed
  15. Phase 2 Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Active Psoriatic Arthritis (PsA) Completed
  16. Phase 2 A Study to Evaluate the Safety and Effectiveness of Ustekinumab or Golimumab Administered Subcutaneously (SC) in Patients With Sarcoidosis Completed
  17. Phase 2 A Safety and Effectiveness Study of CNTO 1275 in Patients With Moderate to Severe Plaque-type Psoriasis Completed
  18. Phase 2 A Study of Ustekinumab (STELARA®) in Adult Japanese Participants With Severe Atopic Dermatitis Completed
  19. Phase 2 Efficacy and Safety of BMS-986165 Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Completed
  20. Phase 2 Ustekinumab (STELARA) for the Treatment of Active Sight-Threatening Uveitis (STAR Study) Completed
  21. Phase 2 Safety and Efficacy Study of JNJ-64304500 in Participants With Moderately to Severely Active Crohn's Disease Completed
  22. Phase 2 Efficacy of Ustekinumab Followed by Abatacept for the Treatment of Psoriasis Vulgaris Completed
  23. Phase 2 Pilot Study of Ustekinumab for Subjects With Chronic Atopic Dermatitis Completed
  24. Phase 1 Pilot Trial of Ustekinumab for Primary Sjögren's Syndrome Completed
  25. Phase 1 A Study to Assess the Effect of Ustekinumab (Stelara®) and Etanercept (Enbrel®) in Participants With Moderate to Severe Psoriasis (MK-0000-206) Completed
  26. Phase 1 An Open-Label and Long-Term Extension Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Patients With Ichthyoses Completed
  27. N/A Efficacy and Safety of Ustekinumab in Patients With Moderate to Severe Palmar Plantar Psoriasis Completed

Showing the 33 most-cited and recently-updated of 33 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Network meta-analysis compares biologics and targeted drugs for systemic lupus erythematosus efficacy and safety
Infectious Disease Meta-analysis
Network meta-analysis compares biologics and targeted drugs for systemic lupus erythematosus efficacy and safety New Lupus Treatments Show Stronger Results With Fewer Side Effects
This systematic review and network meta-analysis of 17,121 patients with systemic lupus erythematosus compared biologics and targeted small …
Certain new lupus drugs help more people feel better with fewer flare-ups, especially those struggling with rashes or joint pain that older …
Frontiers May 2, 2026
FDA Approves Stelara (ustekinumab) for moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis
Dermatology FDA Approval
FDA Approves Stelara (ustekinumab) for moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis The FDA approved a drug called Stelara to treat several inflammatory conditions in adults and children
The FDA approved ustekinumab for adult and pediatric patients 6 years and older with moderate to severe plaque psoriasis and active psoriati…
FDA approved Stelara to treat moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis in adults an…
FDA Apr 21, 2026
FDA Approves Stelara (ustekinumab) for moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis
Dermatology FDA Approval
FDA Approves Stelara (ustekinumab) for moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis The FDA has approved a new drug called Stelara for several inflammatory conditions
The FDA approved ustekinumab for adult and pediatric patients 6 years and older with moderate to severe plaque psoriasis and active psoriati…
The FDA has approved Stelara to treat moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis in a…
FDA Apr 21, 2026
Network meta-analysis finds biologics superior to placebo for pediatric plaque psoriasis
Dermatology Meta-analysis
Network meta-analysis finds biologics superior to placebo for pediatric plaque psoriasis Biologic treatments help children with moderate to severe psoriasis, analysis finds
A network meta-analysis of randomized controlled trials including 1,016 pediatric psoriasis patients found all biologic therapies significan…
Biologic medicines help children with moderate to severe psoriasis achieve clear skin and better quality of life, analysis finds.
Apr 8, 2026
Phase 3 trial compares bimekizumab to placebo and ustekinumab for moderate to severe plaque psoriasis
Rheumatology Phase III
Phase 3 trial compares bimekizumab to placebo and ustekinumab for moderate to severe plaque psoriasis Can a new psoriasis drug outperform an established treatment?
A phase 3 randomized controlled trial enrolled 567 adults with moderate to severe chronic plaque psoriasis to compare bimekizumab against pl…
A new psoriasis drug called bimekizumab is being tested against existing treatments in a major trial involving 567 adults to see if it helps…
CT.gov Mar 30, 2026
Vedolizumab with Adalimumab or Ustekinumab Studied for Crohn's Endoscopic Response
Gastroenterology Phase IV
Vedolizumab with Adalimumab or Ustekinumab Studied for Crohn's Endoscopic Response Can New Drug Combinations Offer Hope for Crohn's Disease Sufferers?
Phase 4 trial investigates vedolizumab with adalimumab or ustekinumab in Crohn's. Primary endpoint: endoscopic response at 26 weeks.
Adults with moderate to severe Crohn's disease may find new relief by combining vedolizumab with adalimumab or ustekinumab before continuing…
CT.gov Mar 27, 2026